British Columbia (BC) Cancer Agency leads a clinical trial that reveals a new drug has helped reduce the risk of death by 33% in med with prostate cancer that has spread.
Reported by the Vancouver Sun, the double-blind study on the androgen receptor inhibitor called apalutaminde was conducted in 23 countries at 260 cancer centers. The study involved 1,052 men whose median age was 68. The study was sponsored by Janssen.
The Study Findings
The findings of the TITAL (Targeted Investigational Treatment Analysis of Novel Anti-Androgen) trial, which began in 2015, was published in the New England Journal of Medicine (NEJM).
Results were recently presented by BC’s Cancer Agency’s Dr. Kim Chi at ASCO Chicago. Chi, an oncologist, reported overall survival rate is only about 5 years once prostate cancer has spread beyond the prostate, so new treatments are desperately needed. The percentage of patients who took the drug whose cancer did not spread was 68.2%, but In the placebo group the proportion was 47.5%, reports the Vancouver Sun. There was a 33% reduction in the risk of death for those who took the drug. Follow the link to learn more.
About Apalutaminde (Erleada)
A nonsteroidal antiandrogen (NSAA) is medication used for prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC).
The drug was originated by the University of California system and was developed primarily by Janssen Research & Development, a division of Johnson and Johnson. It was first described in the literature in a U.S. patent application that was published November 2007 and in another that was submitted in July 2010. A March 2012 publication described the discovery and development of apalutamide. A Phase I clinical trial of apalutamide was completed March 2012, and the results of this study were published in 2013. Information on Phase III clinical studies, including ATLAS, SPARTAN, and TITAN was published between 2014 and 2016. Positive results for Phase III studies were first described in 2017, and Janssen submitted a New Drug Application for apalutamide to the US FDA on 11 October 2017. Apalutamide was approved by the FDA in the US under the brand name Erleada for the treatment of NM-CRPC 14 February, 2018.
Dr. Kim Chi, BC Cancer Agency